Ryan Fiehler

Title: The Innovative Contributions of Ryan Fiehler

Introduction

Ryan Fiehler is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of immuno-oncology through his innovative patents. With a total of 2 patents, Fiehler's work focuses on advancing cancer treatment methodologies.

Latest Patents

Fiehler's latest patents include a bispecific antibody designed for ICOS and PD-L1. This multispecific antibody is structured in an mAb2 format, incorporating an ICOS-binding Fab region and a PD-L1-binding Fcab region. The application of this antibody is particularly relevant in immuno-oncology, especially for the treatment of solid tumors. Additionally, he has developed combination therapies that include antibodies targeting other immune checkpoint molecules such as PD-1 and CTLA-4, alongside anti-ICOS and anti-PD-L1. Another significant patent involves FC binding fragments that contain a PD-L1 antigen-binding site. These specific binding members are intended for use in treating cancer, infectious diseases, and inflammatory conditions.

Career Highlights

Throughout his career, Ryan Fiehler has worked with prominent companies in the biotechnology sector. Notable among these are F-star Therapeutics, Inc. and Kymab Limited. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Fiehler has collaborated with several professionals in his field, including Mihriban Tuna and Francisca Wollerton Van Horck. These collaborations have further enhanced his research and development efforts.

Conclusion

Ryan Fiehler's contributions to the field of immuno-oncology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment methodologies.